hVIVO contract the fruit of increasing Asian focus | News Direct

hVIVO contract the fruit of increasing Asian focus

hVIVO PLC
Digital Asset Direct by hVIVO PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | January 04, 2023 08:37 AM Eastern Standard Time

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Proactive after announcing the signing of a £5.2mln contract with a biotech company in the Asia Pacific region to test the latter's respiratory syncytial virus (RSV) vaccine candidate. Khan says that the deal is the first hVIVO has signed in Asia in a decade, and is the result of the research company's increasing focus on growing its sales in the region

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthPharma & BiotechRespiratoryRSVVaccine